Your browser doesn't support javascript.
loading
Clinical Efficacy and Safety of Low-Level Laser Therapy in Patients with Perennial Allergic Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
Jung, Hahn Jin; Chung, Young-Jun; Choi, Young-Seok; Chung, Phil Sang; Mo, Ji-Hun.
Afiliação
  • Jung HJ; Department of Otorhinolaryngology-Head and Neck Surgery, Chungbuk National University College of Medicine, Chungbuk National University Hospital, Cheongju 361711, Korea.
  • Chung YJ; Department of Otorhinolaryngology, Dankook University College of Medicine, Cheonan 31116, Korea.
  • Choi YS; Beckman Laser Institute Korea, Dankook University College of Medicine, Cheonan 31116, Korea.
  • Chung PS; Laser Translational Clinical Trial Center, Dankook University Hospital, Cheonan 31116, Korea.
  • Mo JH; Department of Otorhinolaryngology-Head and Neck Surgery, Chungbuk National University College of Medicine, Chungbuk National University Hospital, Cheongju 361711, Korea.
J Clin Med ; 10(4)2021 Feb 15.
Article em En | MEDLINE | ID: mdl-33671931
ABSTRACT
Allergic rhinitis (AR) is a common disease that interferes with the daily activities and reduces the quality of life. Conventional treatments often do not provide complete resolution of the symptoms, and many new treatment modalities have been tried. This study aimed to evaluate the efficacy and safety of low-level laser therapy (LLLT) for AR in a randomized, double-blind, placebo-controlled trial. Patients diagnosed with AR were randomly allocated to receive LLLT or sham treatment. The primary outcome was a change in the reflective total nasal symptom score (TNSS). The secondary outcome was quality of life scores assessed using the Rhinoconjunctivitis Quality of Life Questionnaire. Incidences of adverse events were also recorded. Among 67 randomized subjects, 41 subjects (22 in LLLT group and 19 in sham treatment group) were included for efficacy analysis. The LLLT group showed a significantly improved TNSS score compared to the sham treatment group for decreasing AR symptom severity (p = 0.011) and improving quality of life regarding nasal symptoms (p = 0.036) at the end of treatment. Throughout the treatment period, no severe adverse events occurred. This clinical trial showed that LLLT is an effective and safe option for the management of AR regarding symptom relief and quality of life improvement.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: J Clin Med Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: J Clin Med Ano de publicação: 2021 Tipo de documento: Article
...